Societe Generale’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Societe Generale’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$212K	Buy	+5,728	New	+$225K	﹤0.01%	2088

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Societe Generale's PBE Position: Q2 2016 in Review

Societe Generale opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q2 2016: 5,728 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #2088 among its holdings.

73 funds tracked by Wall St. Rank hold PBE as of Q2 2016.

Societe Generale held 5,728 shares of Invesco Biotechnology & Genome ETF worth $212K as of Q2 2016.
Invesco Biotechnology & Genome ETF was a new Societe Generale position in Q2 2016.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2088 holding.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.